<DOC>
	<DOC>NCT00130182</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and effectiveness of two dose strengths of study drug compared to placebo in pediatric patients with cystic fibrosis (CF).</brief_summary>
	<brief_title>A Study in Pediatric Patients With Cystic Fibrosis Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<criteria>Have confirmed diagnosis of CF Have an FEV1 greater than or equal to 60% Have oxygen saturation greater than or equal to 90% on room air Be clinically stable for at least 4 weeks prior to screening Be able to reproducibly perform spirometry maneuvers Have clinically significant comorbidities Have changed their physiotherapy technique or schedule within 7 days prior to screening Using prior and concurrent medications according to protocol</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>lung disease</keyword>
</DOC>